NAPSRx

The collaboration between Daiichi Sankyo and Charleston Labs marks a significant venture for the pain management market.

The Medicine Company has secured FDA approval for ORBACTIV adding to their product pipeline of innovative medicines worldwide.

Actavis plc (NYSE: ACT) is a specialty pharmaceutical company specializing in developing, manufacturing and commercializing generic drugs and branded pharmaceutical products.

Teva is a manufacturer of generics and specialty pharmaceuticals and is currently the world leader in generic drug sales.

Jardiance® (empagliflozin), a joint therapeutic venture from Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly has been approved to reduce blood sugar levels in adult patients with type 2 diabetes.

The approval of Stiverdi Respimat is another great achievement for Boehringer Ingelheim as they continuously expand on their respiratory product pipeline.

AstraZeneca’s respiratory franchise is expected to see a significant boost with the assumption of Almirall’s pipeline of novel respiratory assets.

Bayer Group had an impressive second quarter for 2014 as earnings climbed based on successful drug launches and the company's established product pipeline.

IMBRUVICA®, a jointly developed therapy from Pharmacyclics, Inc. and Janssen Biotech received full Approval based on Phase 3 RESONATE™ study data

Abbvie is a global biopharmaceutical specializing in the discovery and advancement of innovative therapies to meet the health needs of people and societies around the globe.